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The relationship between oral contraceptives pills (OCP) and body weight gain has long been established and 
remains one of the major setback of OCP. This study herefore, was designed to establish the effect of OCP in 
rabbits. It was a six weeks study involving 15 female rabbits that were divided into three groups (A, B, and C). 
Group A served as the control, while B and C served as the test groups involving rabbits with lower and higher 
weights respectively. Weight changes were determined  three phases: during 2 weeks of acclimatization; during 2 
weeks post acclimatization (without OCP administration); and during 4 weeks post acclimatization (with OCP 
administration in the last 2 weeks). Throughout the period of the study, water, rabbit feed and grasses were given ad 
libitum. The results showed weight gain after acclimatization and after the next 2 weeks without OCP administration 
in all the groups. However, during OCP administration, weight gain (+0.06kg) was observed in group A, but weight 
loss (-0.06kg) in group C, while no weight change was observed in group B. The results of this study suggest 
therefore, that there is a need for further studies particularly on the dosing pattern of OCP. 
 




The increasing population no doubt puts strain on the world’s resources such as land/space, water/food and clean air.  
In this regards, ESHRE Capri Workshop Group (2005) stated that “at a global level, contraception has played 
important role in helping to reduce overcrowding, pressures on resources, pollution, global warming, ad  loss of 
animal species due to loss of habitat”. Although the prevalence of contraceptive usage has increased worl wide, oral 
contraceptives are among the most extensively studied and used medications in the world (Hatcher et al., 1998) 
reason being that they are accessible, does not requires doctor’s prescription, and/or can be gotten over the counter. 
 
Since its introduction some 50 years ago, many studies have been conducted and there are numerous documentations 
on its efficacy and availability. The World Health Organization estimated in 1998, that over 100 million women 
worldwide are on oral contraceptive pills (OCP) (WHO, 1998) and this fact was corroborated by Trussell (2007). 
Despite that however, many women who require continuing contraception, stop using it primarily because of 
tolerability issues, including cycle control, weight gain, water retention, perimenstrual symptoms, and hypertension 
(Bagshaw, 1995; Fotherby and Caldwel, 1994), as well as venous and arterial cardiovascular complications 
(Burkman et al., 2001; Kemmeran et al., 2001; Baillargeon et al., 2005). The minor side effects produced by OCP 
steroids, like nausea, breast tenderness, weight gain, irregular menstrual bleeding as well as thrombosis were 
common and occasionally severe enough to cause discontinuation of use (Avonts et al,, 1990; Henderson et al., 
1991; American College of Obstetricians and Gynecologists 1992; Endrikat et al., 1995). These side effcts are of 
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great clinical importance and have over the years resulted in many important changes in the composition and use of 
these preparations to reduce the side effects. Amongst all the side effects, young women are especially concerned 
with issues of weight gain (Emans et al., 1987), as there is an established relationship between the use of OCP 
containing an estrogen and progestogen, with mean increases in body weight (Weir, 1978; Crane and Harris, 1978; 
WHO. 1989). 
 
Of greater concern, is the fact that despite extensiv  clinical experience, many metabolic effects of OC treatment 
remains to be explored. In fact, there are only few studies evaluating body composition and OCP usage. Ind ed, the 
questions about metabolic effects of OCPs and weight gain are of particular relevance to females during OCP 
treatment. This study therefore, is designed to determine the durational effect of OCP usage on the body weight 
changes in adult female rabbits. 
 
MATERIALS AND METHODS 
 
Experimental Animals: Fifteen adult female rabbits were obtained from Aduwawa market in Benin City, Nigeria, 
and transported to the experiment site where they wre housed in a well-ventilated room under a 12/12 hours 
light/dark cycle and fed feed (Vital feed (Grower pellets produced by Grand Cereals Ltd, a subsidiary of UAO 
Nigeria PLC, Jos, Plateau State), grasses and waterad libitum. 
 
Drug of study: OCP (AVA containing Levonorgestrel 0.15mg and Ethinylestradiol 0.03mg) was purchased from a 
Medical Pharmacy in Ekpoma, Nigeria. AVA 30 ED is a combined oral contraceptive consisting of 21 hormonal 
tablets and 7 non-hormonal tablets. Each white hormonal tablet contains a small amount of two different female 
hormones. These are levonorgestrel (a progestogen) and ethinylestradiol (an estrogen). Because of the small amount 
of hormones, it is considered as a combined low-dose oral contraceptive preparation. 
 
Experimental grouping: The rabbits were divided into three groups (A, B and C) of 5 rabbits each; A served as the 
control, while B (low weight group) and C (high weight group) served as the test groups. 
 
Drug administration: Each day a tablet is dissolved in 100ml distilled water and the appropriate dose per kg was 
measured out using a 2ml syringe for oral administration via an oro-gastric tube. Group B received 0.14mls while 
group C received 0.30ml of the prepared drug. These doses were determined based on comparative dosage per 
weight proportion akin to humans. 
 
Body weight determination: Weight changes were determined in three phases: during 2 weeks of acclimatization 
(phase one); during 2 weeks post acclimatization without OCP administration (phase two); and during 4 weeks post 
acclimatization (with OCP administration in the last 2 weeks) (phase three). Descriptively, phase 1 weight-change 
determination represents body weight changes during acclimatization period that lasted for two weeks. Phase 2 
represents body weight changes during the next 2 weeks after acclimatization without OCP administration, while 
phase 3 represents body weight changes during the ac ual experimental period (2 weeks after phase 2 weight-change 
determination) in which OCP was administered. These weight measurements were conducted weekly, using a goat 
meat weighting scale (China). The mean values were d t rmined and recorded appropriately. 
 
Data analysis: The mean ± standard deviation was determined and one-way ANOVA analyses of variance were 
performed using SPSS version 17 soft ware. The significa ce level was set at p<0.05. Results were present d in 




Mean body weight in groups A, B and C, is presented in table 1, while figures 1 and 2 show graphical 
representations of the mean weight and pattern of weight changes between the groups. As shown in table 1 and 
Figure 1 and 2, mean body weight increased in group A (control). The weight differences in group A were 
significantly higher as the week progresses (Table 1). On the other hand, while weight gain were observed in phase 
1 and 2 of group B and C, mean body weight loss was observed in phase 3, during which OCP was administered. 
These weight changes was significantly different (P>0.05) in group B but not in group C (P>0.05). 
 
Also presented are the differences in weight gain during the three phases (Phase 1, 2 and 3). Group A (control) 
progressively gained weight throughout the study period. Unlike A, group B and C progressively gained weight 
during phase 1 and 2 but during phase 3 as group B showed no change in weight, while group C presented losses in 
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weight (see table 1 and figure 1). Specifically, after acclimatization (phase 1), a weight gain of 0.12kg, 0.20kg and 
0.12kg occurred in group A, B and C respectively. During phase 2, a weight gain of 0.12kg, 0.10kg and 0.10kg 
occurred in group A, B and C respectively. But during phase 3, group A presented a weight gain of 0.06kg, while B 
and C presented an unchanged weight of 0.00kg and a re uction in weight by -0.06kg respectively.   
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Values are mean± Standard deviation and values within t e groups having different superscript are stati ically 








Figure 2: Line graph showing weekly weight changes pattern of rabbits fed oral contraceptive pill 
 




Increase in the world’s population if allowed at the present rate, will surely cause a burden on public health and 
world’s resources. Unfortunately, contraception, which could have countered this phenomenal growth rate, emains 
inadequately utilized due to several known side effts. In fact, several studies have reported that many women stop 
using OCP primarily because of weight gain (Fotherby and Caldwel, 1994; Bagshaw, 1995), which undoubtedly, 
poses a major risk for chronic diseases, including type II diabetes, cardiovascular disease, hypertension, troke and 
certain forms of cancer (WHO, 2009). Bhattacharya et l. (2011), argues however, that despite the controversies 
associated with the use OCPs, its health benefits still outweighs the risks. 
 
Interestingly, the results of this study has shown that OCP may reduce total weight in women who are already on 
weight management therapies, as well as the overweight, who are considering reducing their weight. In line with the 
present finding, some studies evaluating body composition during oral contraceptive treatment have also shown that 
no significant body weight change is associated with OCP usage (Reubinoff et al., 1995; Franchini et al., 1995, 
Lloyd et al., 2002). More recently a Swedish study concluded that a combined oral contraceptive use cannot be a 
predictor for weight increase in the long term (Lindh et al., 2011) as there is also no evidence that modern low-dose 
pills cause weight gain, but yet, the fear of weight ain contributes to the poor drug compliance to OCP, which often 
results in unintended pregnancies, especially among adolescents (Gupta, 2000). 
 
Specifically, a randomized trial confirmed that OCP usage does not cause weight or fat mass gain, at least among 
young female runners (Procter-Gray et al., 2008). Similarly, a Hungarian study comparing two high-dose estrogen 
(both 50 µg ethinyl estradiol) pills, found that women using a lower-dose biphasic levonorgestrel formulation (50 µg 
levonorgestrel x 10 days + 125 µg levonorgestrel x 11 days) showed a significantly lower incidence of weight gain 
as compared to women using a higher-dose monophasic levonorgestrel formulation (250 µg levonorgestrel x 21 
days) (Balogh, 1986). Procter-Gray et al. (2008) however, dichotomizes the argument, stating that OCP usage is 
associated with lean mass gain in eumenorrheic runners but not in those with irregular menses. 
 
Although sex steroids have been shown to interfere with appetite, metabolic functions, and weight, in some women 
using oral contraceptive, the association with OCP treatment however, is unclear (Rickenlund et al., 2004). The 
cause of weight gain as regards increase in hips size, breast, or thigh has been reported to be estrogn, while 
progesterone causes increase in appetite and permannt weight gain (Crystal, 2005). The oral contraceptive pill used 
in this study contains both estrogen (Ethinylestradiol 0.03mg) and progesterone (Levonorgestrel 0.15mg), but yet, a 
weight loss outcome was recorded. Nevertheless, while endogenous androgens are related to abdominal obesity 
(Leenen et al., 1994), exogenous androgen treatment has been shown to reduce body fat and weight in 
postmenopausal women (Gruber et al., 1998). 
 
However, oral administration of estrogen has been fou d to reduce postprandial lipid oxidation and increase fat mass 
(O’Sullivan et al., 1998). In this regards, Rickenlund et al. (2004), reports that the precise mechanisms responsible 
for the increases in weight and body fat remain to be elucidated, but that increase in weight and fat m ss is 
associated with the decline in androgen levels unlike the other hormone where no association was observed with 
hormonal changes 
 
On the other hand, estradiol has been reported to inhibits feeding in animals (Geary, 2001) while high dose 
progestins are appetite stimulating (Maltoni et al., 2001). This fact may support the finding of this study considering 
the low dose progestins (Levonorgestrel 0.15mg) in the OCP used as compared to other OCPs. While Rickenlund et 
al. (2004) reported that sex steroids may exert metabolic effects in adipose tissue, OCPs has been said to also 
decrease insulin sensitivity and the effect on carbohydrate metabolism has been attributed to the progestin 
component (Krauss and Burkman, 1992). Hence, lower doses of estrogen and progesterone in combination (as that 
used in the present study) may elicit anti-obesity properties. 
 
Judging by the findings of this study therefore, one can conclude that OCP, mainly used for birth control, may also 
have potentials for weight management in both the obese and non-obese individuals. Our findings suggest also, that 
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